Uruguayan Centre Of Molecular Imaging

Uruguayan Centre Of Molecular Imaging company information, Employees & Contact Information

At CUDIM, we work every day to transform healthcare in Uruguay and the region. We are leaders in molecular imaging, combining cutting-edge technology, scientific research and a genuine commitment to people's well-being. We offer a wide range of specialised services, including advanced studies such as PET/CT, essential for accurate diagnoses and personalised treatments. In addition, we have state-of-the-art magnetic resonance imaging, which allows detailed assessment of various pathologies, and we perform image-guided biopsies to carry out minimally invasive procedures with high precision. We are the only radiopharmacy in the country dedicated to the production of high quality radiopharmaceuticals (crucial in nuclear medicine and theragnostic therapies) with a particular focus on oncology. We also provide telemedicine services to facilitate remote access to our specialised services and conduct pre-clinical studies to drive scientific research and the development of new therapies and diagnostics. We firmly believe in the power of knowledge, which is why we promote the continuous training of professionals and actively collaborate with academic institutions, contributing to the advancement of science for the benefit of all. With a highly trained team and a vision focused on excellence, we are dedicated to offering an ethical and quality service, reaffirming our commitment to be a reference in innovation in Uruguay, with the aim of caring for life.

Company Details

Employees
41
Founded
-
Address
Américo Ricaldoni, 2010,uruguay
Industry
Hospitals And Health Care
NAICS
Health Care and Social Assistance
Social Assistance
HQ
Montevideo, Montevideo
Looking for a particular Uruguayan Centre Of Molecular Imaging employee's phone or email?

Uruguayan Centre Of Molecular Imaging Questions

News

Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country - Frontiers

Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country Frontiers

Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimer’s Disease: - ACS Publications

Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimer’s Disease: ACS Publications

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant